The Korea Pharmaceutical Bio Association will hold a global IP strategy forum for pharmaceutical bio on the 27th...Discussion on overseas licensing, M&A, patent disputes, etc
Oct 16, 2025
|
The forum, which will be held at the auditorium on the fourth floor of the pharmaceutical center, was organized as intellectual property (IP) issues such as overseas license contracts, M&A, investment, and patent disputes emerged as the core of corporate competitiveness as the pharmaceutical bio industry accelerated its global expansion. Through this, the association plans to strengthen the IP risk management capabilities of domestic pharmaceutical bio companies and seek practical response strategies.
In particular, the forum is expected to be a place to discuss practical solutions based on domestic and international cases amid the growing importance of IP cycle management, from establishing IP strategies in the early stages of drug development to working-level issues at the contract stage, response and financing in the event of disputes.
First, patent attorney Yoon Sun-young of Kim & Chang's law office introduces the design plan of key provisions based on actual contracts under the theme of 「Practical IP Issues of Overseas License Contract」. Choi Sang-kyun, a lawyer at Kim & Chang's law office, will then present the IP rights succession procedure and the due diligence checklist focusing on the "IP management strategy essential for overseas M&A investment".
Yulchon Yoon Kyung-ae, a patent attorney, announces 'IP portfolio construction and patent dispute response strategies for global expansion' and analyzes major global patent dispute types and case-by-case response strategies. Lee Tae-heon, a foreign lawyer at Litik Equity Partners, introduces how to use the TPF (International Dispute Financing System) system as a countermeasure against costs and procedural risks faced by domestic companies in overseas disputes.
After that, a panel discussion will be held under the theme of 'IP strategies and challenges of Korean companies in the global pharmaceutical bio market'. Professor Jung Joon-hyuk of Seoul National University's Graduate School of Law will be in charge of the chair, and officials from Kim & Chang's law firm Yulchon, Litik Equity Partners, Yuhan Corporation, and OMNI Bridgeway (Global TPF Funding Group) will participate in the panel. The panel discussion will cover examples of IP risk management experienced by domestic pharmaceutical bio companies in the process of joint overseas development and the use of funding in overseas pharmaceutical bio sectors, and discuss ways to establish effective IP strategies for domestic companies' global expansion.
An association official said, `As domestic companies expand technical cooperation and investment in the global market, the ability to systematically manage IP risks in advance is becoming increasingly important"This forum will serve as an opportunity for companies to provide practical guidance on global cooperation and conflict response strategies."
This article was translated by Naver AI translator.
